RESUMO
Objective To evaluate the association between RASSF1A Ala133Ser single nucleotide polymorphism (SNP) and colorectal cancer (CRC) in patients of Han population in north China. Methods RASSF1A SNP was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis in 109 colon cancer (CC) patients, 67 rectal cancer (RC) patients and 189 age and sex matched healthy people (as controls). Unconditional logistic regression was used to analyze the gene-disease association and gene-sex interaction. Results The RASSF1A Ala133Ser SNP in CRC patients had no significant difference with that in normal control samples, but the interaction of genotype and sex existed in rectal cancer, Ala/Ser +Ser/Ser genotypes of RASSF1A gene increased the risk of rectal cancer in women (OR=3.78, 95%CI 1.31-10.89). Conclusion The RASSF1A 133Ser allele is associated with rectal cancer in women, but not colon cancer.
RESUMO
Objective To investigate the association between the expression of RASSF1A and Survivin proteins and clinicopathological characteristics in non-small cell lung cancer (NSCLC) and their clinical significance. Methods Expression of RASSF1A and Survivin proteins in the NSCLC tissue microarrays was detected by S-P Immunohistochemistry. Results The positive expression of RASSF1A in NSCLC (46.8 %) was significantly lower than that of in the normal lung tissues (92.9 %) (P < 0.001), but the positive expression of Survivin in NSCLC (78.5 %) was significantly higher than that of in the normal lung tissues (0%) (P<0.001). The percentage of RASSFI A protein expression in the stage Ⅰ and stage Ⅱ of NSCLC was evidently higher than that of in the stage Ⅲ (P<0.001, respectively), however, the percentage of Survivin protein expression in the stage Ⅰ and stage Ⅱ of NSCLC was significantly lower than that of in the stage Ⅲ (P=0.003, P=0.001). The percentage of RASSF1A in NSCLC with lymph node metastasis was observably lower than that of in cases without lymph node metastasis (P<0.05). Furthermore, there was observably negative correlation between expression of RASSF1A protein and that of Survivin protein in NSCLC (r=-0.780, P<0.001). Conclusion The loss expression of RASSF1A protein, over expression of Survivin protein and loss balance of expression of both RASSF1A and Survivin proteins in NSCLC might play important roles in the development and progression of NSCLC; RASSF1A and Survivin proteins might be acted as one helpful molecular marker to predict the lymph node metastasis and the prognosis of NSCLC.
RESUMO
Objective: To study the expression and significance of aberrant methylation of p16 and Ras association domain family A (RASSF1A) in cervical carcinoma. Methods: The cervical samples were divided into three groups: cervical carcinoma (CC) group (n = 40), cervical intraepithelial neoplasia (CIN) group (n =80), and normal control group (n=20). The aberrant methylation of p16 and RASSF1A were detected by using methylation-specific reverse transcriptase polymerase chain reaction (MSP). Results: Methylation of pl 6 and RASSF1A genes were not detected in normal control group. The positive rate of p16 gene methylation was significantly higher in CC group than that in CIN group (40.00% vs 12.5%). The difference was statistically significant (χ2 = 11.88, P < 0.05). The positive rate of RASSFIA gene methylation was significantly higher in CC group than that in CIN group (20.0 % vs 7.5%). There was significant difference (χ2 = 4.04, P < 0.05). The positive rates of RASSF1A and p16 genes methylation were significantly higher in CC group than CIN group (55.0% vs 17.5%). The difference was significant (χ2 = 17.12, P < 0.05). Conclusion: Methylation status in the promoter regions of p16 and RASSF1A genes correlated with biological behaviors of cervical carcinoma. They may provide help in assistant diagnosis and treatment of cervical carcinoma.